Search the Newsreel

Republic Services (RSG) Beats Q2 Earnings and Revenue Estimates

Republic Services (RSG) came out with quarterly earnings of $1.85 per share, beating the Zacks Consensus Estimate of $1.81 per share. This compares to earnings of $1.77 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Empowered Funds LLC Has $2.48 Million Stake in Sarepta Therapeutics, Inc. $SRPT

Empowered Funds LLC significantly increased its stake in Sarepta Therapeutics (NASDAQ:SRPT) by 1,898,816.7% in Q1, holding 113,935 shares valued at $2.48 million. Other institutional investors also adjusted their positions, and collective institutional ownership stands at 86.68%. Despite the company beating Q2 earnings and revenue …

FDA Approves Replimune’s Melanoma Drug on Third Attempt

The FDA has approved Replimune Group's melanoma drug, Tudriqev, after two prior rejections due to clinical data quality concerns. Tudriqev is a genetically modified virus injected into tumors to kill cancer cells and activate an immune response. This approval marks the end of a …

KORU Medical (KRMD) CCO vests 75,000 RSUs and withholds shares for taxes

KORU Medical Systems' Chief Commercial Officer, Adam R. Kalbermatten, vested 75,000 Restricted Stock Units (RSUs) on July 28, 2026. Simultaneously, 25,483 shares were withheld at $4.26 per share to cover tax obligations. These transactions were reported as direct holdings and were not part of …

US FDA approves Replimune's skin cancer drug after prior rejections

The U.S. FDA has approved Replimune's drug Tudriqev, in combination with Bristol Myers Squibb's Opdivo, for a difficult-to-treat form of advanced melanoma. This approval marks Replimune's first marketed product after previous rejections, and the drug will compete with Iovance Biotherapeutics' Amtagvi. The decision was …

Republic Services, Inc. Reports Second Quarter 2026 Results

Reported Earnings Per Share of $1.84 and Adjusted Earnings Per Share of $1.85 Generated Year-to-Date Cash Flow from Operations of $2.38 Billion and Adjusted Free Cash Flow of $1.58 Billion Invested Approximately $860 Million in Value-Creating Acquisitions During the First-Half of 2026 Increased Full-Year …

Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen

Replimune announced that the FDA has granted accelerated approval for TUDRIQEVTM (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who have progressed on anti-PD-1 therapy. This approval is based on objective response rate and duration of response from the …

Melanoma therapy after anti-PD-1 progression gets FDA accelerated approval

Replimune announced that the FDA has granted accelerated approval for TUDRIQEV in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that has progressed on anti-PD-1 therapy. This approval is based on results from the Phase 1/2 IGNYTE trial, showing a 24.2% objective …

Sarepta Faces Competitive Pressures Despite Pipeline Updates, RBC Says

Sarepta Therapeutics (SRPT) is seeing a new strategic focus under its recently appointed CEO, with m PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

Sarepta Therapeutics (SRPT) reported Q2 2026 adjusted earnings and total revenues that beat analyst estimates, despite a significant year-over-year decline in both figures, primarily due to lower Elevidys sales. The company updated its 2026 net product revenue guidance and raised its collaboration and other …

KORU Medical Systems, Inc. Stock 12‑Month Price Target Cut to $6.6, Implies 60% Upside

Analysts have slightly reduced the 12-month average price target for KORU Medical Systems, Inc. (KRMD) stock from $6.8 to $6.6, implying a 60% potential upside based on the Aug. 5 closing price. The consensus rating among 5 analysts remains a "Buy," with 4 analysts …

OLD REPUBLIC ANNOUNCES STRATEGIC HIRE AT OLD REPUBLIC EXCESS & SURPLUS

CHICAGO, Aug. 6, 2026 /PRNewswire/ -- Old Republic International Corporation (NYSE: ORI) – today announced that John Paulk has been appointed Chief Operating Officer of Old Republic Excess & Surplus, reporting to Ralph Sabbagh, President. In making this announcement, Craig Smiddy, Old Republic International's …

Old Republic's New Unit COO Brings 20 Years' Experience

Old Republic International Corporation (NYSE: ORI) has appointed John Paulk as Chief Operating Officer of Old Republic Excess & Surplus. Paulk brings over two decades of executive experience in the specialty E&S insurance sector, and will focus on optimizing business performance and driving operational …

Sarepta’s new CEO Michael Severino faces critical milestones to prove growth

Sarepta Therapeutics' new CEO, Michael Severino, is navigating critical upcoming milestones that will determine the company's growth trajectory, including regulatory decisions for its Duchenne muscular dystrophy gene therapy Elevidys and exon-skipping treatments. Elevidys sales saw a sequential drop, though patient enrollment forms are increasing, …

Sarepta Narrows 2026 Revenue Guidance on Elevidys Q2 Sales Dip

Sarepta Therapeutics reported a 34 percent decline in Q2 2026 revenue, primarily due to lower sales of its Duchenne muscular dystrophy gene therapy, Elevidys, following an FDA label narrowing last year. Despite this, the company beat Wall Street's revenue and EPS estimates. Sarepta has …

AMREP Corp (AXR) Earnings Forecast: Future EPS & Revenue Growth Estimates

AMREP Corp (AXR) has an earnings forecast score of 6.00, ranking 37th in the Construction & Engineering industry. Analysts have a consensus price target of $30.00 for AXR, with one analyst currently rating the stock as "Hold." The company's expected revenue for the next …

Sarepta Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:SRPT) 2026-08-06

Sarepta Therapeutics reported strong financial performance in Q2 2026, with GAAP operating income of $13 million and non-GAAP operating income of $86 million, and cash and investments growing to $945 million. The company narrowed its 2026 net product revenue guidance to $1.2 billion-$1.3 billion …

BioLife Solutions (NASDAQ: BLFS) plans cash-stock merger with Repligen

Republic Services (RSG) Earnings Date and Reports 2026 $RSG

Republic Services invested ~$860M in first-half acquisitions; dividend up ~7%

Intrepid Potash (IPI) Stock Faces Profit Pressure Despite Better Margins

Intrepid Potash (IPI) stock, trading at a P/E of 28.5x, saw a slight share price slip despite improved gross margins and adjusted EBITDA in Q2 2026. While operational efficiencies and higher realized prices for TRIO and potash supported a bullish outlook, net income from …

Sarepta forecasts $1.2B-$1.3B 2026 net product revenue as Cohort 8 12-week data shifts to Q1 2027

Earnings Call Insights: Sarepta Therapeutics (SRPT) Q2 2026 MANAGEMENT VIEW * “This is my first earnings call as CEO of Sarepta...” and “we have narrowed 2026 total net product revenue guidance to $1.2 billion to $1.3 billion, with a mid-point being the appropriate reference,” …

Intrepid Potash Inc (IPI) (Q2 2026) Earnings Call Highlights: Strong Margin Growth and Raised ...

Key Points Interested in Intrepid Potash, Inc? Here are five stocks we like better. Profitability improved in Q2: Adjusted EBITDA rose to $17.5 million from $13.8 million, while gross margin increased 35% to $16.6 million, driven by stronger Trio margins and improved potash operations. …

Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary

Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Platform Evolution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

Sarepta Therapeutics (SRPT) reported $401.25 million in revenue for the quarter ended June 2026, representing a year-over-year decline of 34.3%. EPS of $0.64 for the same period compares to $2.02 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $355.55 …

KORU Medical Systems, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:KRMD) 2026-08-05

KORU Medical Systems, Inc. (KRMD) published a slide deck in conjunction with their Q2 2026 earnings call. This presentation provides details related to their financial results for the second quarter of 2026. The article was written by SA Transcripts, which is responsible for publishing …

Informe de resultados de Sarepta: supera las estimaciones del segundo trimestre de 2026 y sus acciones suben en el mercado fuera de horario

Sarepta Therapeutics Q2 2026 Earnings Call Transcript

Sarepta Therapeutics reported strong financial performance in Q2 2026, with GAAP operating income of $13 million and non-GAAP operating income of $86 million, and cash and investments growing to $945 million. The company narrowed its 2026 net product revenue guidance to $1.2 billion-$1.3 billion …

Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm

If you purchased or acquired stock in Replimune and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648. Click here to participate in the action. …

California State Teachers Retirement System Raises Holdings in Repligen Corporation $RGEN

The California State Teachers Retirement System increased its stake in Repligen Corporation (NASDAQ:RGEN) by 22.1% in the first quarter, now holding 61,860 shares valued at $7.3 million. Repligen exceeded analyst expectations with quarterly revenue of $204.13 million and earnings of $0.54 per share, and …

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 …

Earnings call transcript: Intrepid Potash tops Q2 2026 estimates on stronger margins

Intrepid Potash (IPI) reported improved Q2 profitability, raising its full-year production guidance for potash and Trio fertilizer and announcing plans for share repurchases. The company's performance was driven by better process control and recovery across operations, leading to increased gross margin and adjusted EBITDA …

Intrepid Potash Releases Q2 2026 Financial Results

Intrepid Potash, Inc. reported strong Q2 2026 earnings, with an adjusted EPS of $0.56, significantly beating the analyst forecast of $0.38. Despite a slight revenue dip to $66.7M, the company achieved $15.6M in net income, driven by strong performance in its Trio® segment. Wall …

Intrepid Potash, Inc. 2Q 2026: Revenue $66.69M, Net income $15.58M, EPS $1.17— 10-Q Summary

Intrepid Potash, Inc. reported its second-quarter 2026 financial results, with revenue of $66.69M, net income of $15.58M, and diluted EPS of $1.17. The company saw significant year-over-year increases in net income and EPS, largely due to higher net realized prices for potash and Trio, …

Sarepta Therapeutics Navigates FDA Hold on Elevidys in Expanding DMD Market

Sarepta Therapeutics is facing an FDA clinical hold on its Duchenne muscular dystrophy (DMD) therapy, Elevidys, due to safety concerns over acute liver failure, even as the global DMD market is projected to reach US$62.13 billion by 2030. Despite the hold, Sarepta has five …

Sarepta set to report earnings as new CEO faces ELEVIDYS test

Sarepta Therapeutics is poised to release its second-quarter earnings, with investors keenly observing the performance of its gene therapy ELEVIDYS under new CEO Michael Severino. The company faces scrutiny over whether ELEVIDYS sales can stabilize after a recent decline and safety concerns, impacting market …